Dec. 4 at 6:28 PM
Wegovy prices are falling but remain confusingly inconsistent due to complex U.S. drug pricing rules and new direct-pay models. Public prices range from Novo Nordisk’s
$1,349 list price to
$199–
$349 for cash-pay programs,
$350 on TrumpRx, and as low as
$50 for Medicare users in 2027. Experts say there’s no precedent for such wide variation, driven by policies, coupons, and compounded versions sold via telehealth platforms like Hims & Hers.
The fragmented system leaves patients unsure what they will actually pay, despite rising transparency. While GLP-1 drugs like Wegovy are cheaper than a year ago, it remains unclear whether direct-pay initiatives will deliver savings. A cash-pay patient may spend
$3,900 a year, versus
$600 for someone on Medicare, underscoring affordability concerns despite broader access.
$NVO $HIMS $GDRX $LLY